RecruitingNCT04890067

Observational Study in Localized Osteosarcoma

Multicenter Observational Study on the Treatment of Patients With Localized Osteosarcoma


Sponsor

Italian Sarcoma Group

Enrollment

120 participants

Start Date

Jul 30, 2021

Study Type

OBSERVATIONAL

Conditions

Summary

Observational prospective trial aimed to collect the collect demographic, clinical, surgical, pathological and molecular characteristics and treatment from patients affected by localized OsteoSarcoma (OS) treated according the AIEOP/Italian Sarcoma Group (ISG) OS 2021


Eligibility

Max Age: 40 Years

Plain Language Summary

Simplified for easier understanding

This observational study is following children and young adults with high-grade osteosarcoma (a type of bone cancer) of the arms or legs who are being treated with standard chemotherapy. The goal is to collect data to better understand how this cancer behaves and how different patients respond to treatment. **You may be eligible if...** - You are 40 years old or younger at the time of diagnosis - You have been diagnosed with high-grade osteosarcoma of the limbs (arms or legs) - Your disease is localized (has not spread to distant organs; skip metastases within the limb are okay) - You have adequate organ function to receive recommended chemotherapy - You (or your parents/guardian if you are a minor) have given written consent **You may NOT be eligible if...** - Your cancer has spread to distant parts of the body (metastases) - You have a different subtype of osteosarcoma (periosteal, parosteal, or secondary) - You have a medical condition that prevents you from receiving the recommended treatment Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERTreatment of Osteosarcoma according the AIEOP/ISG OS 2021 recommendations (includes drugs, surgery, radiotherapy or any other received treatments)

This observational study collects all the treatments received by the patients according according the AIEOP/ISG OS 2021 and therefore includes drug/biological/surgical/ radiotherapy and any other applicable treatments


Locations(16)

Centro di Riferimento Oncologico - Unit of Medical Oncology

Aviano, Pordenone, Italy

Sandra Aliberti

Candiolo, Torino, Italy

IRCCS materno infantile Burlo Garofolo

Trieste, T, Italy

Azienda Ospedaliero Universitaria Consorziale Policlinico - Bari

Bari, Italy

IRCCS Istituto ortopedico Rizzoli

Bologna, Italy

A.O. Universitaria Policlinico S. Orsola Malpighi di Bologna

Bologna, Italy

AUO Policnico G. Rodolico San Marco

Catania, Italy

A.O. Universitaria Meyer

Florence, Italy

Istituto Giannina Gaslini

Genova, Italy

Fondazione IRCCS INT Milano SC Pediatria Oncologica

Milan, Italy

FONDAZIONE IRCCS Istituto Nazionale dei Tumori

Milan, Italy

Azienda Ospedaliera di Padova UOC Oncoematologia Pediatrica

Padova, Italy

ARNAS P. O. "Civico e Benfratelli"

Palermo, Italy

Azienda Ospedaliero-Universitaria Pisana

Pisa, Italy

Istituti Fisioterapici Ospitalieri di Roma

Roma, Italy

Ospedale Pediatrico Bambin Gesu'

Roma, Italy

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04890067


Related Trials